Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective
Due to the high prostate cancer incidence worldwide, the development of different methods of treatment continues to be a hot research topic. Since its first clinical application at the beginning of the 2010s, abiraterone in the form of prodrug abiraterone acetate continues to be the most used hormon...
Saved in:
| Main Authors: | Ivana Z. Kuzminac, Andrea R. Nikolić, Marina P. Savić, Jovana J. Ajduković |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/16/11/1401 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Usage, effectiveness and safety of abiraterone in prostate cancer
by: J. M. Caro Teller, et al.
Published: (2014-03-01) -
Compatibility of hypokalaemia caused by low-dose prednisolone plus abiraterone acetate therapy for metastatic castration-resistant prostate cancer
by: Shota Torii, et al.
Published: (2024-11-01) -
Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01) -
An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer
by: Yi Wu, et al.
Published: (2025-01-01) -
Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)